Piper Sandler analyst Adam Maeder lowered the firm’s price target on Inari Medical to $50 from $55 and keeps a Neutral rating on the shares following quarterly results. All-in the print was solid, in the firm’s view, but Piper still awaits additional visibility into the U.S. core VTE franchise before becoming more constructive on shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical Reports First Quarter 2024 Financial Results
- Inari Medical management to meet with BTIG
- Inari Medical to Announce First Quarter 2024 Financial Results
- Inari Medical Announces the Release of 2023 Ethos and Sustainability Report
- Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives